NELFB and breast cancer: To determine whether the same was true for human NELFB, we used CRISPR-Cas9 in human breast cancer cells MDA-MB-231 to disrupt the corresponding C-terminal portion of human NELFB (hNELFB), which is over 90% identical to its mouse counterpart (Fig. S2, A and B).